Research programme: cholinergic receptor modulators - AlphaSyx TherapeuticsAlternative Names: AT 5355
Latest Information Update: 05 Nov 2016
At a glance
- Originator AlphaSyx Therapeutics
- Class Small molecules
- Mechanism of Action Cholinergic receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Neurogenic inflammation
Most Recent Events
- 02 Nov 2016 Preclinical trials in Neurogenic inflammation in USA (unspecified route)